Company profile
Xencor Inc
NASDAQ:XNCRBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| PLAMOTAMAB | phase2 | — | 3 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (29)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07284797 | phase1 | recruiting | 2026-02-24 | 2028-10-01 | Xencor, Inc. | A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases |
| NCT07230353 | phase1 | recruiting | 2025-10-21 | 2028-06-01 | Xencor, Inc. | A Phase 1b Open-label Study to Evaluate Safety of Plamotamab in Participants With Rheumatoid Arthritis |
| NCT05032040 | phase2 | active_not_recruiting | 2022-07-21 | 2025-10-15 | Xencor, Inc. | A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies |
| NCT03411915 | phase1 | completed | 2018-01-22 | 2021-10-26 | Xencor, Inc. | A Study of XmAb®18087 in Subjects With NET and GIST |
| NCT03517488 | phase1 | completed | 2018-07-10 | 2022-06-01 | Xencor, Inc. | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors |
FDA applications (0)
No records yet.